← Leaderboards
Matthias Stephan
Massachusetts Institute Of Technology
$9,559,593
Attributed
$10,849,886
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,849,886 · 6
By mechanism
R01$10,746,370 · 5
F32$103,516 · 1
Top collaborators
- Eric C Holland3 shared
- A. Mcgarry Houghton3 shared
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorImmuneDesignT-LymphocytePharmaceutical PreparationsNanoparticleCancer PatientPolymersPhenotypeInjectableCellsTechnologyImmune SystemMalignant NeoplasmsLymphocyteTumor ImmunityImmunityIn VivoInfusion ProceduresAntibodiesProgramsGenesMalignant Neoplasm Of OvaryBase
Grant awards (27)
Rational in situ programming of cancer vaccine-responding T-cell clones$473,651
R01 · FY2025 · CA · contact PI
Developing macrophage reprogramming mRNA nanocarriers for initial clinical testing$639,059
R01 · FY2024 · CA · contact PI
Rational in situ programming of cancer vaccine-responding T-cell clones$449,968
R01 · FY2024 · CA · contact PI
Developing macrophage reprogramming mRNA nanocarriers for initial clinical testing$664,289
R01 · FY2023 · CA · contact PI
Rational in situ programming of cancer vaccine-responding T-cell clones$446,342
R01 · FY2023 · CA · contact PI
Developing macrophage reprogramming mRNA nanocarriers for initial clinical testing$669,177
R01 · FY2022 · CA · contact PI
Rational in situ programming of cancer vaccine-responding T-cell clones$464,178
R01 · FY2022 · CA · contact PI
Developing macrophage reprogramming mRNA nanocarriers for initial clinical testing$518,545
R01 · FY2021 · CA · contact PI
Rational in situ programming of cancer vaccine-responding T-cell clones$384,876
R01 · FY2021 · CA · contact PI
Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers$253,224
R01 · FY2021 · CA · contact PI
Developing macrophage reprogramming mRNA nanocarriers for initial clinical testing$169,133
R01 · FY2021 · CA · contact PI
Rational in situ programming of cancer vaccine-responding T-cell clones$126,644
R01 · FY2021 · CA · contact PI
Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers$107,543
R01 · FY2021 · CA · contact PI
Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers$360,766
R01 · FY2020 · CA · contact PI
Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers$360,766
R01 · FY2019 · CA · contact PI
Using genetically engineered mouse models of brain tumors to develop therapeutic nanoparticles & biomaterials$633,241
R01 · FY2018 · CA
Preventing tumor relapse with biomaterial-supported lymphocyte implants$405,870
R01 · FY2018 · CA · contact PI
Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers$371,925
R01 · FY2018 · CA · contact PI
Using genetically engineered mouse models of brain tumors to develop therapeutic nanoparticles & biomaterials$644,838
R01 · FY2017 · CA
Preventing tumor relapse with biomaterial-supported lymphocyte implants$403,989
R01 · FY2017 · CA · contact PI
Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers$371,925
R01 · FY2017 · CA · contact PI
Using genetically engineered mouse models of brain tumors to develop therapeutic nanoparticles & biomaterials$657,360
R01 · FY2016 · CA
Preventing tumor relapse with biomaterial-supported lymphocyte implants$408,426
R01 · FY2016 · CA · contact PI
Preventing tumor relapse with biomaterial-supported lymphocyte implants$419,624
R01 · FY2015 · CA · contact PI
Preventing tumor relapse with biomaterial-supported lymphocyte implants$341,011
R01 · FY2014 · CA · contact PI
Therapeutic cell engineering using surface-conjugated synthetic nanoparticles$53,042
F32 · FY2011 · EB · contact PI
Therapeutic cell engineering using surface-conjugated synthetic nanoparticles$50,474
F32 · FY2010 · EB · contact PI